Introduction
============

About 67% of physician office visits involve a prescription medication \[[@ref1]\]. This rises to 80% when the visit is to an emergency department \[[@ref1]\]. Ideally, the provider should discuss the prescriptions' benefits and side effects with the patient. However, the scheduling realities of single visits restrict patient contact time and the information that can be presented. Unfortunately, providers often do not discuss medication side effects, and so on with patients \[[@ref2],[@ref3]\].

Inevitably, and reasonably, patients seek out additional information. One source of this information is the Internet, including pharma websites. It is not an exaggeration to say that the use of the Internet to search for medical information is ubiquitous. In 2012, 72% of Internet users looked for medical information on the Web, and this percent has been increasing with time \[[@ref4]-[@ref6]\]. Whereas the quality of Web-based information varies greatly, unfettered access to information on the Internet is critical to patients trying to educate themselves. In order to make a truly autonomous decision, patients must have whatever information they feel is necessary. Whereas providers may not have the time to review all of the information a patient may want to know, searching the Internet is not subject to a time limitation.

The purpose of this study was to investigate a convenience selection of pharma websites in order to determine whether there is information labeled as for "professionals-only" (eg, not for patients), and what one needs to do in order to access this information. We discuss our findings within the ethical framework of Western medicine, including respect for autonomy and truth telling.

Methods
=======

We examined a convenience sample of 40 pharma websites looking for the presence of a "professionals-only" section. Drugs websites to review were selected based on the year of approval by the Food and Drug Administration (FDA; within the past 3 years), as well as a sample of commonly prescribed medications. There was no attempt to randomize the selection. All of the researchers reviewed each site to determine whether (1) a "professionals-only" section exists, and (2) whether access to this information requires certifying that one is a health care professional.

This project did not require an institutional review board (IRB) submission because no human (or animal) subjects were involved. As noted in the University of Iowa IRB Statement of Compliance, "The University of Iowa Institutional Review Boards are duly constituted with written procedures for initial and continuing review of human subjects research" \[[@ref7]\]. This research does not include any human subjects.

Results
=======

Of the 40 websites, 36 (90%) contained information or a link to information that was restricted to professionals only ([Table 1](#table1){ref-type="table"}). Twenty-four (67%, 24/36) of these 36 sites required an attestation that the user was a US health care professional before the information could be accessed ([Table 1](#table1){ref-type="table"}). Another 12 (33%, 12/36) of the 36 contained "professionals-only" information that was accessible without such an attestation. [Figures 1](#figure1){ref-type="fig"} and [2](#figure2){ref-type="fig"} are screenshots that show of the type of verification required in order to access "professionals only" information. Researchers agreed on the categorization of all sites.

![An example of a "professionals only" attestation statement from a drug company website.](jmir_v19i5e178_fig1){#figure1}

![An example of a "professionals only" attestation statement from a drug company website.](jmir_v19i5e178_fig2){#figure2}

###### 

Results of website evaluation.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Trade name      Drug name                                                            Website                   Embargoed information   Comments
  --------------- -------------------------------------------------------------------- ------------------------- ----------------------- ------------------
  Abilify         Aripiprazole                                                         www.abilify.com           Yes^a^                  \

  Amyvid          Florbetapir F18 injection                                            www.amyvid.com            Yes                     \

  Anoro Ellipta   Umeclidinium and vilanterol inhalation powder                        www.myanoro.com           Yes                     \

  Briinta         Ticagrelor                                                           www.briinta.com           Other^b^                \

  Brintellix      Vortioxetine                                                         www.brintellix.com        Other                   \

  Corlanor        Ivabradine                                                           www.corlanor.com          Yes                     \

  Cometriq        Cabozantinib                                                         www.cometriq.com          Yes                     \

  Crestor         Rosuvastatin                                                         www.crestor.com           Yes                     \

  Cyramza         Ramucirumab injection                                                www.cyramzahcp.com        Yes                     \

  Dexilant        Dexlansoparzole                                                      www.dexilant.com          Other                   \

  Duavee          Conjugated estrogens or bazedoxifene                                 www.duavee.com            Other                   \

  Eliquis         Apixiban                                                             www.eliquis.com/eliquis   Yes                     \

  Entresto        Sacubitril or valasartan                                             www.entresto.com          Other                   \

  Erivedge        Vismodegib                                                           www.erivedge.com/         Yes                     \

  Farxiga         Dapagliflozin                                                        www.farxiga.com           Yes                     \

  Focalin XR      Dexmethylphenidate                                                   www.focalinxr.com         No^c^                   \

  Gazyva          Obinutuzumab                                                         www.gazyva.com            Yes                     \

  Invokana        Canagliflozon tablets                                                www.invokana.com          Yes                     \

  Harvoni         Edipasvir and sofosbuvir                                             www.harvoni.com           Yes                     \

  Kadcyla         Ado-trastuzumab emtansine                                            www.kadcyla.com           Yes                     \

  Kalydeco        Ivacaftor                                                            www.kalydeco.com          Yes                     \

  Kynamro         Mipomersen sodium                                                    www.kynamro.com           Yes                     Requires sign-up

  Lipitor         Atorvastatin                                                         www.lipitor.com           No                      \

  Myalept         Metreleptin for injection                                            www.myalept.com           Yes                     \

  Nesina          Alogliptin                                                           www.nesinahcp.com         Other                   \

  Otezla          Apremilast                                                           www.otelza.com            Other                   \

  Picato          Ingenol mebutate                                                     www.picato.com            Yes                     \

  Pomalyst        Pomalidomide 29                                                      www.pomalyst.com          Yes                     \

  Pradaxa         Dabigitran                                                           www.dabigitran.com        Yes                     \

  Praluent        Alirocumab                                                           www.praluent.com          Yes                     \

  Pristiq         Desvenlofaxine                                                       www.pristiq.com           Other                   \

  Savaysa         Edoxaban                                                             www.savaysa.com           Other                   \

  Sovaldi         Sofosbuvir                                                           www.sovaldi.com           Other                   \

  Stribild        Elvitegravir, cobicistat, emtricitabine, tenofovir, and disoproxil   www.stribild.com          Other                   \

  Tanzeum         Albiglutide                                                          www.tanzeum.com           Yes                     \

  Tecfidera       Dimethyl fumarate                                                    www.tecidera.com          Yes                     \

  Voraxaze        Glucarpidase                                                         www.voraxze.com           Yes                     \

  Vraylar         Cariprazine                                                          www.vraylar.com           Yes                     \

  Vyvanse         Lisdexamfetamine                                                     www.vyvanse.com           Other                   \

  Xarelto         Rivoroxiban                                                          www.xarelto.com           Other                   \
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Yes = embargoed "professionals-only" information requiring attestation.

^b^Other = professionals-only information but no attestation required.

^c^No = no "professionals-only" information.

Discussion
==========

Principal Findings
------------------

Restricting access to information as implemented by these websites has several implications. In the first instance, patients may not have access to desired information. Anything that limits a patient's knowledge has the potential to adversely impact autonomy \[[@ref8],[@ref9]\]. It can be argued that patient-oriented pharma websites contain complete information and already present all of the information that a patient needs in a useable form. Whereas it might be intuited that this solves the problem of information access, patient-oriented pharma websites may present a skewed view of drug risks and benefits and often contain advertising designed to entice the patient \[[@ref10]-[@ref12]\]. One might also argue that the lack of access to "professionals-only" information can be mitigated by the US FDA (the agency responsible for the approval and safety of drug in the United States) having made it a requirement that pharma advertising allow patient access to the package insert, including Web-based advertising \[[@ref13]\]. However, the language of packaging information (and medical information on the Web in general) is written at a level that is often incomprehensible to the general public \[[@ref14]-[@ref20]\]. Thus, providing unfettered access to the "professionals-only" information will not in itself solve the problem of lack of accessibility; enhanced readability and a better presentation of information would generally be needed for the information consuming public. This is not an unsurmountable barrier; difficult information can be presented in a manner that is accessible to the general public \[[@ref19]\]. We can enhance individuals' ability to make autonomous choices by improving the quality of information presentation.

One can argue that consumers can get the same information elsewhere on the Internet (eg, wikis, sites such as drugs.com). This creates a fundamental dilemma, however. For patients to know what information is missing from their current knowledge base, they first need to access the "professionals-only" information. Thus, the argument that the same information is available elsewhere fails. This may be the case but the uncertainty in patients' minds will continue.

A second, and perhaps more troubling, dilemma arises when there is "professional-only" information on pharma websites that requires an attestation as to one's status as a health care provider. The patient can then either (1) not access the information or (2) lie about their status as a professional. Either outcome is unacceptable. Introducing lying into the therapeutic space can have adverse consequents. Requiring patients to lie in order to obtain information sets a bad precedent. If lying is tacitly accepted as part of the medical system, it has the potential to undermine one of the pillars on which medicine is built; truth telling. Worse still, the system that a patient would like to have faith in is enticing them to lie. Forcing patients to lie may challenge one's faith in the truthfulness of other aspects of care and the medical system \[[@ref21],[@ref22]\].

Finally, "professionals-only" information can suggest that health care professionals have some dark, mysterious secrets to be hidden from the public. Patients might legitimately wonder what it is that we health care professionals have to hide. Such concerns might further undermine trust in the medical system. Such distrust, whether generated by the perception that there is information hidden from the patient or because of the requirement to lie in the medical sphere, translates into worse patient outcomes \[[@ref23],[@ref24]\].

It is true that patients can become overwhelmed with information. One solution is to have providers act as interpreters of information; this is the model preferred by many patients \[[@ref21]\]. This puts the onus on providers; unfortunately, providers often do not do a particularly good job of laying out the benefits and harms of therapy either \[[@ref25]\]. However, a provider-patient partnership with the provider interpreting information for the patient and directing the patient to reliable Web-based information can be a viable model \[[@ref26]\].

Limitations
-----------

We did not look at the content of "professionals-only" websites and compare this with the content of the patient-oriented websites. For the purposes of our study, such a comparison is a secondary consideration and would not change the study outcome; our main purpose here is to highlight the ethical issues surrounding "professionals-only" websites needing an attestation. A follow-up study could be designed to examine the issue of content. However, no matter the outcome of such an analysis, the basic dilemma remains; patients have to lie to get to "professionals-only" content or do without this information. If the content of the patient and the professional is the same, why require an attestation which may prompt the patient to lie? If the content of the professionals-only and patient-only websites are different, why are we not providing patients with the same information that we are providing to professionals (albeit presented in a manner appropriate for lay-people)?

A second weakness of our study is that we only looked at a small sample of pharma websites. It is possible, but unlikely, that many other pharma websites do not have embargoed information. Nonetheless, we have shown that there is a potential problem related to embargoed information, lying, and trust.

Conclusions
-----------

In conclusion, pharma websites often have a "professionals-only" section where access requires user attestation that she is a health care provider. Three problems follow. First, limited access potentially restricts patient information and therefore autonomy. Second, nonaccess may suggest that professionals have "something to hide." Finally, such a system may "train" or induce patients to lie in other medical interactions. Distrust of the medical system may ensue.
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